Drug intelligence / Profile preview

triamcinolone + prednisone

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral, Topical, Intramuscular

Overview

Triamcinolone and prednisone are both corticosteroids that work by decreasing inflammation and suppressing the immune system. They are used to treat various inflammatory conditions including allergic reactions, asthma, arthritis, skin disorders, autoimmune diseases, and many other conditions. When used in combination, they may have similar mechanisms of action but different pharmacokinetic profiles, with triamcinolone often being administered as an injection or topical preparation and prednisone typically taken orally.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on triamcinolone + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on triamcinolone + prednisone.

Explore the full profile